Immunovant Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2018 | — | $-1.5M | — |
| Jun 2018 | — | $-411.0K | — |
| Jul 2018 | — | $-411.0K | — |
| Sep 2018 | — | $2.3M | — |
| Dec 2018 | — | $8.0M | $325.0K |
| Mar 2019 | — | $7.3M | $7.0M |
| Jun 2019 | — | $-12.1M | $1.9M |
| Sep 2019 | — | $-23.3M | $1.6M |
| Dec 2019 | — | $111.9M | $123.5M |
| Mar 2020 | — | $94.1M | $100.6M |
| Jun 2020 | — | $267.8M | $280.3M |
| Sep 2020 | — | $438.4M | $444.4M |
| Dec 2020 | — | $414.2M | $422.0M |
| Mar 2021 | — | $391.5M | $400.1M |
| Jun 2021 | — | $365.5M | $379.0M |
| Sep 2021 | — | $536.4M | $559.0M |
| Dec 2021 | — | $505.1M | $527.0M |
| Mar 2022 | — | $469.8M | $493.8M |
| Jun 2022 | — | $436.5M | $427.2M |
| Sep 2022 | — | $395.7M | $405.8M |
| Dec 2022 | — | $414.7M | $432.6M |
| Mar 2023 | — | $362.5M | $376.5M |
| Jun 2023 | — | $299.9M | $330.0M |
| Sep 2023 | — | $251.8M | $269.9M |
| Dec 2023 | — | $679.3M | $690.9M |
| Mar 2024 | — | $617.8M | $635.4M |
| Jun 2024 | — | $544.7M | $560.0M |
| Sep 2024 | — | $449.1M | $472.9M |
| Dec 2024 | — | $352.6M | $374.7M |
| Mar 2025 | — | $707.4M | $714.0M |
| Jun 2025 | — | $608.5M | $598.9M |
| Sep 2025 | — | $519.7M | $521.9M |
| Dec 2025 | — | $986.1M | $994.5M |
| Mar 2026 | — | $852.6M | $902.1M |
| Jun 2026 | — | $735.4M | $797.8M |